AIDS and Behavior

, 10:85 | Cite as

Disclosure of HIV Status and Adherence to Daily Drug Regimens Among HIV-infected Children in Uganda

  • Winnie Bikaako-KajuraEmail author
  • Emmanuel Luyirika
  • David W. Purcell
  • Julia Downing
  • Frank Kaharuza
  • Jonathan Mermin
  • Samuel Malamba
  • Rebecca Bunnell
Original Paper


Pediatric adherence to daily drug regimens has not been widely assessed in Africa where majority of HIV infected children live. Using in-depth interviews of 42 HIV-infected children taking ART and/or cotrimoxazole prophylaxis, and 42 primary caregivers, at a comprehensive HIV/AIDS clinic in Uganda, we evaluated their adherence experiences for purposes of program improvement. Daily drug regimens provided by the pediatric clinic included cotrimoxazole prophylaxis as well as ART and cotrimoxazole combined. Complete disclosure of HIV status by caregivers to children and strong parental relationships were related to good adherence. Structural factors including poverty and stigma were barriers to adherence even for children who had had complete disclosure and a supportive relationship with a parent. To ensure adherence to life-extending medications, our findings underscore the need for providers to support caregivers to disclose, provide on-going support and maintain open communication with HIV-infected children taking cotrimoxazole prophylaxis and ART.


Pediatrics AIDS Adherence Antiretrovirals Cotrimoxazole 



We thank Mildmay Centre staff and clients and Centres for Disease Control staff for all their time and efforts. E. Ezati, R. Nasaba, J. Kalyebara, R. Ingabire and M. Butamanya conducted the interviews, R. Apondi, S. Nakayiwa and F. Bloom with data analysis and S. Bechange and R. Batamwita assisted with data management. We also thank G. Rutherford, R. King and R. Stall, for their comments on earlier versions of this manuscript and T. Wamala for her assistance with the references.


  1. African Network for the Care of Children Affected by AIDS (2004). Handbook on paediatric AIDS in Africa.Google Scholar
  2. Belzer, M. E., Fuchs, D. N., Luftman, G. S., & Tucker, D. J. (1999). Antiretroviral adherence issues among HIV-positive adolescents and young adults. Journal of Adolescent Health, 25, 316–319.PubMedCrossRefGoogle Scholar
  3. Blasini, I., Chantry, C., Cruz, C., Ortiz, L., Salabarria, I., Scalley, N., & Matos, B. (2004). Disclosure model for pediatric patients living with HIV in Puerto Rico: Design, implementation, and evaluation. Journal of Developmental and Behavioral Pediatrics, 25, 181–189.PubMedCrossRefGoogle Scholar
  4. Boni, S., Pontali, E., De, G. P., Pedemonte, P., & Bassetti, D. (2000). Compliance to combination antiretroviral therapy in HIV-1 infected children. International Journal of Antimicrobial Agents, 16, 371–372.PubMedCrossRefGoogle Scholar
  5. Chintu, C., Bhat, G. J., Walker, A. S., Mulenga, V., Sinyinza, F., Lishimpi, K., & Farrelly, L. (2004). Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): A double-blind randomised placebo-controlled trial. Lancet, 364, 1865–1871.PubMedCrossRefGoogle Scholar
  6. Elise, A., France, A. M., Louise, W. M., Bata, D., Francois, R., Roger, S., & Philippe, M. (2005). Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Cote d’Ivoire. Journal of Acquired Immune Deficiency Syndromes, 40, 498–500.PubMedCrossRefGoogle Scholar
  7. Fassinou, P., Elenga, N., Rouet, F., Laguide, R., Kouakoussui, K. A., Timite, M., & Blanche, S. (2004). Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d’Ivoire. AIDS, 18, 1905–1913.PubMedCrossRefGoogle Scholar
  8. Lester, P., Chesney, M., Cooke, M., Whalley, P., Perez, B., Petru, A., & Dorenbaum, A. (2002). Diagnostic disclosure to HIV-infected children: How parents decide when and what to tell. Clinical Child Psychology and Psychiatry, 7, 85–99.CrossRefGoogle Scholar
  9. Martinez, J., Bell, D., Camacho, R., Henry-Reid, L. M., Bell, M., Watson, C., & Rodriguez, F. (2000). Adherence to antiviral drug regimens in HIV-infected adolescent patients engaged in care in a comprehensive adolescent and young adult clinic. Journal of the National Medical Association, 92, 55–61.PubMedGoogle Scholar
  10. Mehta, S., Moore, R. D., & Graham, N. M. (1997). Potential factors affecting adherence with HIV therapy [editorial]. AIDS, 11, 1665–1670.PubMedCrossRefGoogle Scholar
  11. Mermin, J., Lule, J., Ekwaru, J. P., Malamba, S., Downing, R., Ransom, R., & Kaharuza, F. (2004). Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4 cell count, and HIV viral load among persons with HIV in rural Uganda. Lancet, 364, 1428–1434.PubMedCrossRefGoogle Scholar
  12. Murphy, D. A., Sarr, M., Durako, S. J., Moscicki, A. B., Wilson, C. M., & Muenz, L. R. (2003). Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Archives of Pediatric Adolescent Medicine, 157, 249–255.CrossRefGoogle Scholar
  13. Murphy, D. A., Wilson, C. M., Durako, S. J., Muenz, L. R., & Belzer, M. (2001). Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care, 13, 27–40.PubMedCrossRefGoogle Scholar
  14. Reddington, C., Cohen, J., Baldillo, A., Toye, M., Smith, D., Kneut, C., & Demaria, A. (2000). Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatric Infectious Disease Journal, 19, 1148–1153.PubMedCrossRefGoogle Scholar
  15. Shingadia, D., Viani, R. M., Yogev, R., Binns, H., Dankner, W. M., Spector, S. A., & Chadwick, E. G. (2000). Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus. Pediatrics, 105, E80.PubMedCrossRefGoogle Scholar
  16. Steele, R. G., Anderson, B., Rindel, B., Dreyer, M. L., Perrin, K., Christensen, R., & Tyc, V. (2001). Adherence to antiretroviral therapy among HIV-positive children: Examination of the role of caregiver health beliefs. AIDS Care, 13, 617–629.PubMedCrossRefGoogle Scholar
  17. Steele, R. G., & Grauer, D. (2003). Adherence to antiretroviral therapy for pediatric HIV infection: Review of the literature and recommendations for research. Clinical Child Family Psychology Review, 6, 17–30.CrossRefGoogle Scholar
  18. Temple, M. E., Koranyi, K. I., & Nahata, M. C. (2001). The safety and antiviral effect of protease inhibitors in children. Pharmacotherapy, 21, 287–294.PubMedCrossRefGoogle Scholar
  19. UNAIDS. (2004). Report on the global HIV/AIDS epidemic: 4th global report. [Retrieved from:].Google Scholar
  20. van Dyke, R. B., Lee, S., Johnson, G. M., Wiznia, A., Mohan, K., Stanley, K., & Morse, E. V. (2002). Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics, 109, 1–7.CrossRefGoogle Scholar
  21. van Rossum, A. M., Fraaij, P. L., & de Groot, R. (2002). Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infectious Disease, 2, 93–102.CrossRefGoogle Scholar
  22. Watson, D. C., & Farley, J. J. (1999). Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatric Infectious Disease Journal, 18, 682–689.PubMedCrossRefGoogle Scholar
  23. Waugh, S. (2003). Parental views on disclosure of diagnosis to their HIV-positive children. AIDS Care, 15, 169–176.PubMedCrossRefGoogle Scholar
  24. Williams A., & Friedland, G. (1997). Adherence, compliance, and HAART. AIDS Clinical Care, 9, 51–54, 58.PubMedGoogle Scholar
  25. World Health Organization. (2006). Who expert consultation on cotrimoxazole prophylaxis in HIV infection. [Retrieved from:].Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Winnie Bikaako-Kajura
    • 1
    • 4
    Email author
  • Emmanuel Luyirika
    • 2
  • David W. Purcell
    • 3
  • Julia Downing
    • 2
  • Frank Kaharuza
    • 1
  • Jonathan Mermin
    • 1
  • Samuel Malamba
    • 1
  • Rebecca Bunnell
    • 1
  1. 1.CDC-Uganda, Global AIDS ProgramKampalaUganda
  2. 2.The Mildmay Centre, UgandaKampalaUganda
  3. 3.Division of HIV/AIDS Prevention, National Center for HIV, STD and TB PreventionCenters for Disease Control and PreventionAtlantaUSA
  4. 4.Centers for Disease Control and Prevention, UgandaC/O Uganda Virus Research InstituteEntebbeUganda

Personalised recommendations